Business Description
Verici Dx is a UK-based medical diagnostics company, founded in 2020, that develops specialized tests to improve outcomes for kidney transplant patients in the United Kingdom and the United States. Its core products include Tutivia, which detects rejection of a transplanted kidney, and Protega, a blood-based test that predicts the likelihood of long-term transplant failure. The company also provides genomic analysis and data science services, helping researchers and clinicians better understand complex diseases including multiple sclerosis and long COVID. Through partnerships with research institutions and commercial partners, Verici Dx works to bring its testing solutions to patients and healthcare providers across multiple markets.
